Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 20/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 13/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 12/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36206 | 0.85 | S1PR3 (0.66) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL36337 | 0.84 | S1PR3 (0.87) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL35933 | 0.83 | S1PR3 (0.67) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL36013 | 0.81 | S1PR3 (0.63) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL36123 | 0.80 | S1PR3 (0.66) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL35626 | 0.80 | S1PR3 (0.71) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL35942 | 0.80 | S1PR3 (0.71) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL35951 | 0.80 | S1PR3 (0.63) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL805669 | 0.77 | S1PR3 (1.00) | S1PR3S1PR1S1PR2LPAR2S1PR4 | |
| SCHEMBL35846 | 0.76 | S1PR3 (0.67) | S1PR3S1PR1S1PR2LPAR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513220-B2 | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | claimed |
| EP-2569322-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2013-03-20 | — | — | EP | claimed |
| US-20130018019-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2013-01-17 | — | — | US | claimed |
| WO-2011143332-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | WO | claimed |
| US-20110281822-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-8513220-B2 | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513220-B2 | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity | ALLERGAN, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2569322-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130018019-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018019-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011143332-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281822-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018019-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | S1PR1, S1PR3, S1PR2 | S1PR3 2/4885S1PR1 1/4885S1PR2 3/4885 |
| US-20110281822-A1 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY | S1PR1, S1PR3, S1PR2 | S1PR3 2/4885S1PR1 1/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.